Compare TransMedics Group Inc (TMDX) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs VICI Properties Inc — how do they compare? TransMedics Group Inc trades at $78.15 (market cap $2.74B), while VICI Properties Inc trades at $22.92 (market cap $25.09B). The key difference: VICI Properties Inc is far larger — about 9.2× TransMedics Group Inc's market cap, and VICI Properties Inc pays a 8.07% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and VICI Properties Inc for 43 Days on average.
| TMDX | VICI | |
|---|---|---|
Market Cap | $2.74B | $25.09B |
Volume | 949,331 | 17,066,337 |
Sector | Health | Real Estate |
52-Week High | $150.42 | $31.42 |
52-Week Low | $61.99 | $22.53 |
Typical Hold Time | 24 Days | 43 Days |
Enterprise Value | $3.13B | $42.65B |
Dividend Yield | — | 8.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
VICI Properties trades at $22.88, down 1.06% with a bearish technical signal despite strong fundamentals including a 67.5% net income margin and attractive valuation at 8.83 P/E. The stock shows mixed earnings performance with recent misses but maintains robust cash flow and dividend coverage. Recent news highlights tenant diversification through new leases while addressing market concerns about regional casino exposure and rising interest rates.
The investment case balances deep value metrics against sector headwinds, with analyst consensus strongly bullish ($28.90 target) but technical weakness suggesting near-term pressure. Key opportunities include the 7.8% dividend yield with 1.3x coverage, while risks center on tenant concentration and interest rate sensitivity in the REIT structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
